We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 05, 2022

Cardiovascular Outcomes of Evening vs Morning Dosing of Antihypertensives

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial
Lancet 2022 Oct 22;400(10361)1417-1425, IS Mackenzie, A Rogers, NR Poulter, B Williams, MJ Brown, DJ Webb, I Ford, DA Rorie, G Guthrie, JWK Grieve, F Pigazzani, PM Rothwell, R Young, A McConnachie, AD Struthers, CC Lang, TM MacDonald

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading